



## **Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting**

May 15, 2018

WAYNE, Pa., May 15, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in aesthetic and medical dermatology and immunology, has provided an unrestricted educational grant for the symposium on Janus Kinase (JAK) inhibitors at the International Investigative Dermatology (IID) 2018 Meeting in Orlando, Florida. The symposium, titled "JAKs Be Nimble: New Applications of JAK Inhibitors in Dermatology," will be held in the Gatlin D-E room of the Rosen Shingle Creek Resort on Thursday, May 17, 2018, from 12:00-1:30 PM ET.

"JAK inhibitors appear to be quite versatile molecules when it comes to treating inflammatory skin diseases, which is exciting. The fact that we could fill a symposium with presentations discussing new observations about treatment with these drugs within the past year is very telling," notes symposium moderator John E. Harris, M.D., Ph.D., Associate Professor of Dermatology, University of Massachusetts Medical School.

The following abstracts are scheduled to be presented at the symposium:

- Tofacitinib for recalcitrant cutaneous dermatomyositis. Abeer Alsarheed, Cambridge, MA. Abstract #503
- CXCL9 drives morphea pathogenesis in mice. Druhmil Patel, Worcester, MA. Abstract #102
- Photosensitivity and heightened type I IFN responses in cutaneous lupus are driven by elevated interferon kappa. Mrinal Sarkar, Ann Arbor, MI. Abstract #072
- Tofacitinib leads to increased infections by downregulation of antiviral immune defense. Heike C. Hawerkamp, Dusseldorf, Germany. Abstract #1056
- RAGE mediates UVB-induced persistent DNA Damage Response (DDR) and resistance to apoptosis in human melanocytes. Lynn A. Cornelius, St. Louis, MO. Abstract #1215
- Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia. Jindapa Thummakriengkrai, Thammasat University, Thailand. Abstract #1311
- Efficacy of oral tofacitinib in the treatment of lichen planopilaris. Brigitte Sallee, MD, New York, NY. Abstract #491

### **About Aclaris Therapeutics, Inc.**

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris' focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, androgenetic alopecia, and vitiligo. For additional information, please visit [www.aclaristx.com](http://www.aclaristx.com) and follow Aclaris on LinkedIn.

### **Cautionary Note Regarding Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris' clinical development of its JAK inhibitor drug candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2017 and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "Financial Information" section of the Investors page of Aclaris' website at <http://www.aclaristx.com>. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Aclaris Contact  
Michael Tung, M.D.  
Senior Vice President  
Corporate Strategy/Investor Relations  
484-329-2140  
[mtung@aclairstx.com](mailto:mtung@aclairstx.com)



Source: Aclaris Therapeutics, Inc.